Testing faster radiation therapy combined with immunotherapy for advanced lung cancer

Plain-English translation of NCT06102057 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a faster, more focused form of radiation therapy—guided by a special type of scanning—works better than standard radiation therapy for advanced lung cancer that cannot be operated on. All participants receive during radiation, and then a medication called durvalumab to help the immune system fight remaining cancer cells. The study aims to see if this accelerated approach improves outcomes while managing side effects.

Standard treatment for this type of advanced lung cancer has limitations, and doctors want to know if delivering radiation more quickly and precisely to smaller areas of disease, combined with , can improve survival and quality of life for these patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with stage III non-small cell lung cancer that cannot be surgically removed
you are 18 years or older
your cancer shows a specific marker (PD-L1 expression of at least 1%) that makes it likely to respond to immunotherapy
you are healthy enough to tolerate both chemotherapy and radiation treatment simultaneously, as determined by your medical team
you have adequate lung, heart, liver, and kidney function based on recent blood tests and breathing tests

You likely don't qualify if…

you are pregnant or breastfeeding, or unwilling to use reliable contraception during treatment
you have severely reduced lung function below the minimum thresholds required for this treatment
you have inadequate bone marrow or organ function (low blood counts, liver or kidney problems)
you are unable to attend regular clinic visits and follow-up appointments as scheduled

What participation looks like

You will be randomly assigned to receive either standard radiation with or the faster, focused radiation with . Treatment takes several weeks, during which you'll have regular clinic visits for imaging, blood tests, and monitoring. After completing radiation and , if your cancer responds well, you'll receive the medication (durvalumab) as an infusion every 4 weeks for up to 12 months. The study includes follow-up visits to monitor your health and side effects for at least 90 days after treatment ends, with longer-term survival follow-up for up to 2 years.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Testing faster radiation therapy combined with immunotherapy for advanced lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(11 sites)